TriangleNCT02141282 · OUTCOME
Percentage of Participants With Minimal Residual Disease (MRD) Negativity Status
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported
What was measured
The rate of MRD response is defined as the percentage of participants who had MRD negative status.
Analysis population: All participants in the Main and Expansion Cohorts who received at least one dose of venetoclax; indeterminate or missing samples were considered MRD positive for the calculation
Groups in this outcome
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts
Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts
| Group | Source count |
|---|---|
| ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 91 |
| ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 36 |
Reported measurements
Peripheral blood
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 30.8 | Not reported | 21.5 | 41.3 | Not reported |
| ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 25.0 | Not reported | 12.1 | 42.2 | Not reported |
Bone marrow
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 6.6 | Not reported | 2.5 | 13.8 | Not reported |
| ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 11.1 | Not reported | 3.1 | 26.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 21.5
- upper Limit
- 41.3
- value
- 30.8
- group Id
- OG001
- lower Limit
- 12.1
- upper Limit
- 42.2
- value
- 25.0
- title
- Peripheral blood
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.5
- upper Limit
- 13.8
- value
- 6.6
- group Id
- OG001
- lower Limit
- 3.1
- upper Limit
- 26.1
- value
- 11.1
- title
- Bone marrow
- denoms
- counts
- group Id
- OG000
- value
- 91
- group Id
- OG001
- value
- 36
- units
- Participants
- description
- The rate of MRD response is defined as the percentage of participants who had MRD negative status.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts
- id
- OG000
- title
- ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts
- description
- Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts
- id
- OG001
- title
- ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts
- param Type
- NUMBER
- population Description
- All participants in the Main and Expansion Cohorts who received at least one dose of venetoclax; indeterminate or missing samples were considered MRD positive for the calculation
- reporting Status
- POSTED
- time Frame
- Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported
- title
- Percentage of Participants With Minimal Residual Disease (MRD) Negativity Status
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice